有多少中风幸存者患有有问题的性,需要药物治疗? 一个国际 (欧洲和美国) 观测研究协议
Richard D Zorowitz1, Laura Serrano Barrenechea2, Simon Butet3
1MedStar National Rehabilitation Network and Georgetown University School of Medicine, Washington, District of Columbia, USA richard.zorowitz@medstar.net.
BMJ open
|January 17, 2025
概括
这项研究追踪了幸存者的早期中风后性 (PSS). 它旨在了解PSS如何发展,并识别需要药物治疗的病例.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 临床研究 临床研究
背景情况:
- 卒中幸存者在出院后经常面临诸如中风后 (PSS) 等并发症.
- 目前的护理缺乏对PSS进行适当的随访,PSS是一种常见的中风后并发症.
- 关于需要治疗的"有问题的"PSS早期发展和患病率的数据有限.
研究的目的:
- 研究中风后性 (PSS) 的早期发病和发展.
- 确定中风幸存者中发展到需要药理干预的PSS的比例.
- 提高对PSS进展的理解,并确定未满足的治疗需求.
主要方法:
- 未来的国际观测流行病学研究 (EPITOME).
- 监测了18-90岁的近期首次中风 (4周内) 和的患者.
- 使用远程监测 (PSMQ) 和超过12个月的临床评估来检测和确认PSS.
主要成果:
- 研究正在进行中;结果正在等待出版.
- 数据收集包括远程和临床评估,以确认PSS发病和严重程度.
- 调查评估确定PSS是否受益于药理疗法.
结论:
- 早期发现和表征PSS对于有效的患者管理至关重要.
- 这项研究将为PSS的早期发展轨迹提供关键的见解.
- 研究结果将为PSS中风幸存者开发有针对性的干预措施提供信息.
相关概念视频
Spasmolytic Agents: Chemical Classification
853
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
853
Centrally Acting Muscle Relaxants: Therapeutic Uses
619
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
619
Parkinson's Disease: Treatment
202
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
202
Classification of Skeletal Muscle Relaxants
2.4K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.4K


